A detailed history of Nuveen Asset Management, LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 212,554 shares of DSGN stock, worth $1.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
212,554
Previous 212,554 -0.0%
Holding current value
$1.19 Million
Previous $712,000 60.53%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$3.23 - $4.77 $176,196 - $260,203
54,550 Added 34.52%
212,554 $712,000
Q4 2023

Feb 14, 2024

BUY
$1.99 - $2.76 $9,187 - $12,742
4,617 Added 3.01%
158,004 $418,000
Q3 2023

Nov 14, 2023

SELL
$2.05 - $8.14 $2,361 - $9,377
-1,152 Reduced 0.75%
153,387 $361,000
Q2 2023

Aug 14, 2023

BUY
$4.99 - $7.64 $193,307 - $295,965
38,739 Added 33.45%
154,539 $973,000
Q1 2023

May 15, 2023

BUY
$5.5 - $9.77 $119,504 - $212,282
21,728 Added 23.1%
115,800 $668,000
Q4 2022

Feb 14, 2023

SELL
$7.86 - $17.2 $126,247 - $276,266
-16,062 Reduced 14.58%
94,072 $965,000
Q3 2022

Nov 14, 2022

SELL
$14.09 - $25.57 $18,697 - $33,931
-1,327 Reduced 1.19%
110,134 $1.84 Million
Q2 2022

Aug 15, 2022

BUY
$9.91 - $17.33 $320,915 - $561,197
32,383 Added 40.95%
111,461 $1.56 Million
Q1 2022

May 16, 2022

BUY
$11.17 - $20.89 $66,629 - $124,608
5,965 Added 8.16%
79,078 $1.47 Million
Q4 2021

Feb 14, 2022

BUY
$13.64 - $21.41 $410,127 - $643,755
30,068 Added 69.85%
73,113 $1.32 Million
Q3 2021

Nov 12, 2021

SELL
$13.99 - $20.03 $6,547 - $9,374
-468 Reduced 1.08%
43,045 $696,000
Q2 2021

Aug 16, 2021

BUY
$19.02 - $29.78 $827,617 - $1.3 Million
43,513 New
43,513 $865,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $314M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.